…nths after a relapse; PIRA was defined as sustained disability in a relapse-free patient. During the median 12-year follow-up, 35% experienced a relapse and 39% had new MRI activity despite their initial NEDA status. Overall, 26% of patients experienced an accrual of disability: 14% was attributed to RAW and 12% to PIRA. The median time from treatment start to RAW or PIRA was 10 and 9 years, respectively. There was no difference in the median EDSS…
…spike IgG, with 33.8 binding antibody units (BAU) used as the cut-off. Anti-CoV-2 antibodies were detected in all healthy controls and 100% of patients on natalizumab, 54.8% of patients on ocrelizumab and 40.0% on fingolimod. The antibody response was significantly blunted in patients receiving ocrelizumab or fingolimod (median BAU 59.8 and 21.5, respectively) compared to healthy controls (BAU 1860) or natalizumab patients (BAU 3015). The likeliho…
…of observational studies L. Prosperini et al. Objective: To analysis COVID-19-related mortality in MS patients. Data source: Meta-analysis of published studies (n=60) reporting COVID-19 mortality (n=5474 patients). Results: The crude COVID mortality rate in MS patients was 3.1%. Death rates were higher in studies of patients with comorbidities, progressive disease or receiving treatment with anti-CD20 therapies. Treatment with an interferon-beta…
…ine; 2 cases occurred after the Pfizer vaccine. There was one death in a 44-year-old male who developed dyspnea, quadriplegia and respiratory failure after receiving the AstraZeneca vaccine; MRI lesions were present in the cerebral hemispheres, brainstem and spinal cord. To date, 66 cases of acute demyelinating events have been reported following COVID vaccination but it is not known if this is higher than the background rate. Older age at MS onse…
…to participate in a clinical drug trial; 5% were currently in a trial Most common comorbidities were depression or anxiety (both 30%), hypertension (25%) and hyperlipidemia (15%). Conclusions: There is a considerable delay in MS diagnosis. See also P167 – The effect of sex and race on delays in multiple sclerosis evaluation and diagnosis: an updated analysis. Safadi et al. P168 – Estimating risk of disease reactivation during and after pregnancy i…